Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) General Counsel Jason B. Shandell sold 16,095 shares of the business’s stock in a transaction dated Friday, November 9th. The shares were sold at an average price of $20.99, for a total value of $337,834.05. Following the completion of the transaction, the general counsel now owns 204,805 shares in the company, valued at approximately $4,298,856.95. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

AMPH traded up $0.88 during trading on Friday, reaching $21.59. The company’s stock had a trading volume of 735,306 shares, compared to its average volume of 117,925. Amphastar Pharmaceuticals Inc has a 52-week low of $14.40 and a 52-week high of $21.65. The firm has a market capitalization of $890.44 million, a PE ratio of 56.82, a P/E/G ratio of 8.77 and a beta of 1.38. The company has a current ratio of 1.94, a quick ratio of 1.24 and a debt-to-equity ratio of 0.11.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last announced its quarterly earnings data on Thursday, November 8th. The company reported $0.12 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.11 by $0.01. Amphastar Pharmaceuticals had a positive return on equity of 2.15% and a negative net margin of 3.39%. The company had revenue of $75.54 million for the quarter, compared to analyst estimates of $76.84 million. During the same quarter in the previous year, the company earned $0.07 EPS. The firm’s revenue for the quarter was up 30.5% compared to the same quarter last year. On average, sell-side analysts predict that Amphastar Pharmaceuticals Inc will post 0.1 EPS for the current year.

AMPH has been the topic of a number of analyst reports. BidaskClub raised Amphastar Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Thursday, September 27th. Zacks Investment Research lowered Amphastar Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, August 10th. ValuEngine raised Amphastar Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Friday, August 17th. Needham & Company LLC lowered their price objective on Amphastar Pharmaceuticals from $24.00 to $22.00 and set a “buy” rating on the stock in a report on Friday, August 10th. Finally, Wells Fargo & Co reaffirmed a “buy” rating on shares of Amphastar Pharmaceuticals in a report on Friday. Two analysts have rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $23.00.

Institutional investors and hedge funds have recently made changes to their positions in the business. Piedmont Investment Advisors LLC purchased a new stake in Amphastar Pharmaceuticals in the 2nd quarter valued at approximately $128,000. Meeder Asset Management Inc. boosted its holdings in Amphastar Pharmaceuticals by 259.8% in the 2nd quarter. Meeder Asset Management Inc. now owns 10,486 shares of the company’s stock valued at $160,000 after purchasing an additional 7,572 shares in the last quarter. SG Americas Securities LLC purchased a new stake in shares of Amphastar Pharmaceuticals during the 2nd quarter worth approximately $161,000. Nisa Investment Advisors LLC purchased a new stake in shares of Amphastar Pharmaceuticals during the 3rd quarter worth approximately $221,000. Finally, Cubist Systematic Strategies LLC purchased a new stake in shares of Amphastar Pharmaceuticals during the 2nd quarter worth approximately $295,000. 42.86% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION WARNING: This article was originally posted by Daily Political and is owned by of Daily Political. If you are viewing this article on another publication, it was copied illegally and republished in violation of United States and international copyright legislation. The original version of this article can be read at https://www.dailypolitical.com/2018/11/10/amphastar-pharmaceuticals-inc-amph-general-counsel-jason-b-shandell-sells-16095-shares.html.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States and internationally. It operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients.

Featured Article: Moving Average – How it Helps Investors in Stock Selection

Insider Buying and Selling by Quarter for Amphastar Pharmaceuticals (NASDAQ:AMPH)

Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.